Opthea has completed enrollment of all patients in the COAST Phase 3 pivotal clinical trial investigating sozinibercept in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet Age-related Macular Degeneration. The sozinibercept clinical program includes two Phase 3 pivotal trials, COAST and ShORe. Enrollment in ShORe is expected to be completed in calendar Q2 2024. Opthea intends to report topline results from these two trials by mid-2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on OPT:
- Opthea Completes Enrollment in First Pivotal Trial with Sozinibercept
- Opthea Strengthens Team with Key Clinical and Regulatory Hires
- Opthea to receive remaining $35M under Development Funding Agreement
- Opthea to Receive US$35M Commitment and Additional US$50M Funding
- Opthea Receives A$8.8 million R&D Tax Incentive
